Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company, is pleased to advise
our Chief Executive Officer Steven Lydeamore will be presenting at
Peak Asset Management’s Peak Sky High luncheon in Melbourne on June
1, 2024.
A copy of the presentation slide deck is
available on the Company’s website.
https://www.immuron.com.au/corporate-presentations/
This release has been authorised by the directors of Immuron
Limited.
COMPANY
CONTACT:Steven LydeamoreChief
Executive Officersteve@immuron.com
About
ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian biopharmaceutical company focused on developing
and commercializing orally delivered targeted polyclonal antibodies
for the treatment of infectious diseases.
About
Travelan®Travelan® is an orally administered
passive immunotherapy that prophylactically reduces the likelihood
of contracting travelers’ diarrhea, a digestive tract disorder that
is commonly caused by pathogenic bacteria and the toxins they
produce. Travelan® is a highly purified tabletized preparation of
hyper immune bovine antibodies and other factors, which when taken
with meals bind to diarrhea-causing bacteria and prevent
colonization and the pathology associated with travelers’ diarrhea.
In Australia, Travelan® is a listed medicine on the Australian
Register for Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travelers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and
is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection.
Travelers’
diarrhea (TD)TD is generally
defined as the passage of ≥ 3 unformed stools per 24 hours plus at
least one additional symptom (such as nausea, vomiting, abdominal
cramps, fever, blood/mucus in the stools, or fecal urgency) that
develop while abroad or within 10 days of returning from any
resource-limited destinations (Leung et al., 2006). Diarrhea
continues to be the most frequent health problem among travelers to
destinations in lower- and middle-income regions (Steffen, 2017).
Deployed US military personnel, essentially representing a
long-term traveller population, are particularly affected given
their population dynamics and the context in which they seek care
and treatment (Connor et al., 2012). Diarrhea is the leading
infectious disease threat to the overall health and preparedness of
deployed US armed forces, with diarrheagenic E. coli, Campylobacter
spp., and Shigella spp. among the most commonly reported etiologies
(Riddle et al., 2006).
Immuron
Platform TechnologyImmuron’s
proprietary technology is based on polyclonal immunoglobulins (IgG)
derived from engineered hyper-immune bovine colostrum. Immuron has
the capability of producing highly specific immunoglobulins to any
enteric pathogen and our products are orally active. Bovine IgG can
withstand the acidic environment of the stomach and is resistant to
proteolysis by the digestive enzymes found in the Gastrointestinal
(GI) tract. Bovine IgG also possesses this unique ability to remain
active in the human GI tract delivering its full benefits directly
to the bacteria found there. The underlying nature of Immuron’s
platform technology enables the development of medicines across a
large range of infectious diseases. The platform can be used to
block viruses or bacteria at mucosal surfaces such as the
Gastrointestinal tract and neutralize the toxins they produce.
IMM-124EIMM-124E
was developed using Immuron’s platform technology. IMM-124E is
produced from the colostrum of birthing cattle that have been
immunised during pregnancy with a vaccine containing the outer
antigens of multiple human derived ETEC. A total of 13 ETEC strains
are used in the vaccine to produce high levels of antibodies
against selected surface antigens from the most common strains of
ETEC.
The resultant hyperimmune colostrum IMM-124E from ETEC
vaccinated cows contains significant levels of polyclonal
antibodies specific for ETEC antigens LPS, CFA-I and Flagellin
(Sears et al., 2017).
The antibodies produced in IMM-124E have been
found to have a stronger binding and neutralizing activity (than
the antibodies of unvaccinated cattle) against a wide range of LPS
antigens including both the variable O-polysaccharide region and
the preserved oligosaccharide core ‘R’ region of LPS from the 13
serotypes used in the ETEC vaccine.
IMM-124E is manufactured into a tablet form referred to as
Travelan®.
ReferencesConnor P, Porter CK,
Swierczewski B and Riddle MS. Diarrhea during military deployment:
current concepts and future directions. Curr Opin Infect Dis.
25(5): 546-54; 2012.
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv Ther.
Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T and
Robins-Browne RM. Randomized control trials using a tablet
formulation of hyperimmune bovine colostrum to prevent diarrhea
caused by enterotoxigenic Escherichia coli in volunteers
Scandinavian Journal of Gastroenterology 46: 862– 868; 2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble
DR. Incidence, etiology, and impact of diarrhea among long-term
travelers’ (US military and similar populations): A systematic
review. American Journal of Tropical Medicine and Hygiene. 74(5):
891-900; 2006.
Sears KT, Tennant SM, Reymann MK, Simon R,
Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF.
Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic
Escherichia coli Hyperimmune Bovine Colostrum products. Clinical
and Vaccine Immunology. 24 (8) 1-14; 2017.
Steffen R. Epidemiology of travelers' diarrhea.
J Travel Med. 24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/ and
https://www.travelan.comSubscribe for Immuron News: Here
FORWARD-LOOKING
STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition, and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions, or circumstances on which any such
statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Aug 2023 to Aug 2024